

**This Page Is Inserted by IFW Operations  
and is not a part of the Official Record**

## **BEST AVAILABLE IMAGES**

**Defective images within this document are accurate representations of the original documents submitted by the applicant.**

**Defects in the images may include (but are not limited to):**

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

PGT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 31/215, 31/165, 31/19, 31/195</b>		(11) International Publication Number: <b>WO 99/32104</b>
A1		(43) International Publication Date: 1 July 1999 (01.07.99)
(21) International Application Number: PCT/US98/25744		(81) Designated States: AU, BR, CA, JP, MX, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(22) International Filing Date: 4 December 1998 (04.12.98)		
(30) Priority Data: 08/994,903 19 December 1997 (19.12.97) US		
(71) Applicant: ALCON LABORATORIES, INC. [US/US]; 6201 South Freeway, Fort Worth, TX 76134-2099 (US).		
(72) Inventors: YANNI, John, M.; 2821 Donnybrook Drive, Burleson, TX 76028 (US). HELLBERG, Mark, R.; 5211 Overridge Drive, Arlington, TX 76017 (US).		
(74) Agents: YEAGER, Sally, S. et al.; Alcon Laboratories, Inc., R & D Counsel Q-148, 6201 South Freeway, Fort Worth, TX 76134-2099 (US).		

Published


With international search report.

(54) Title: USE OF 3-BENZOYL-PHENYLACETIC ACIDS, ESTERS, OR AMIDES FOR TREATMENT OF GLC1A GLAUCOMA

(57) Abstract

Compositions of 3-benzoylphenylacetic acid derivatives for treating GLC1A glaucoma and methods for their use are disclosed.

Concentrations of Unidentified Radioactivity in Ocular Tissues Following a Single 0.3% Topical Ocular Dose of <sup>14</sup>C-AL-6515



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## USE OF 3-BENZOYL-PHENYLACETIC ACIDS, ESTERS, OR AMIDES FOR TREATMENT OF GLC1A GLAUCOMA

5        This invention is directed to the use of certain non-steroidal cyclooxygenase inhibitors for treating glaucoma or ocular hypertension resulting from altered expression of the GLC1A gene (hereinafter GLC1A or 1q glaucoma) in an individual.

10        **Background of the Invention**

      The glaucomas are a heterogeneous group of optic neuropathies characterized by cupping of the optic nerve head, thinning of the retinal nerve fiber layer due to loss of retinal ganglion cells, and specific pathognomonic changes in visual fields. Elevated  
15        intraocular pressure (IOP) is a very important risk factor for the development of most common forms of glaucoma (Sommer A, et al., "Relationship Between Intraocular Pressure and Primary Open Angle Glaucoma Among White and Black Americans," *Arch. Ophthalmol.*, 109:1090-1095 (1991)).

20        A family history of glaucoma also is an important risk factor for the development of glaucoma. It appears that a significant portion of glaucoma is inherited (or at least the risk for developing glaucoma is inherited) although it is often difficult to establish clear inheritance patterns for most of the glaucomas because of the disease onset late in life and the slowly progressive clinical manifestations of the disease. Despite these problems, a  
25        number of families with heritable forms of glaucoma have been identified and these families have been used to map a variety of glaucoma genes (Sheffield, et al., "Genetic Linkage of Familial Open Angle Glaucoma to Chromosome 1q21-q31," *Nature Genetics*, 4:47-50 (1993); Sarfarazi, et al., "Assignment of a Locus (GLC3A) for Primary Congenital Glaucoma (Buphthalmos) to 2p21 and Evidence for Genetic Heterogeneity,"  
30        *Genomics*, 30:171-177 (1995); Akarsu, et al., "A Second Locus (GLC3B) for Primary Congenital Glaucoma (Buphthalmos) Maps to the 1p36 Region," *Human Molecular Genetics*, 5(8):1199-1203 (1996); Stoilova, et al., "Localization of a Locus (GLC1B) for

Adult-Onset Primary Open Angle Glaucoma to the 2cen-q13 Region," *Genomics*, 36:142-150 (1996); Wirtz, et al., "Mapping a Gene for Adult-Onset Primary Open-Angle Glaucoma to Chromosome 3q," *Am. J. Hum. Genet.*, 60:296-304 (1997); Andersen, et al., "A Gene Responsible for the Pigment Dispersion Syndrome Maps to Chromosome 7q35-q36," *Arch. Ophthalmol.*, 115:384-388 (1997). The first glaucoma gene mapped (GLC1A) was in a large family with autosomal dominant inherited juvenile glaucoma (JG). This disease is characterized by an early disease onset (at the age of late teens to early 20s), relatively high IOPs, and general resistance to conventional pharmacological IOP lowering therapy. The GLC1A gene was mapped by positional cloning and linkage analysis to chromosome 1q22-q25 (Sheffield et al, *Id.*, and a number of other groups have confirmed the 1q location of this juvenile glaucoma gene (Richards, et al., "Mapping of a Gene for Autosomal Dominant Juvenile-Onset Open-Angle Glaucoma to Chromosome 1q," *Am. J. Hum. Genet.*, 54:62-70 (1994); Morissette, et al., "A Common Gene for Juvenile and Adult-Onset Primary Open-Angle Glaucomas Confined on Chromosome 1q," *Am. J. Hum. Genet.*, 56:1431-1442 (1995); Wiggs, et al., "Genetic Linkage of Autosomal Dominant Juvenile Glaucoma to 1q21-q31 in Three Affected Pedigrees," *Genomics*, 21:299-303 (1994); Meyer, et al., "Age-Dependent Penetrance and Mapping of the Locus for Juvenile and Early-Onset Open-Angle Glaucoma on Chromosome 1q (GLC1A) in a French Family," *Hum. Genet.*, 98:567-571 (1996); Graft et al., "Confirmation of Linkage to 1q21-31 in a Danish Autosomal Dominant Juvenile-Onset Glaucoma Family and Evidence of Genetic Heterogeneity," *Hum. Genet.*, 96:285-289 (1995). Glaucoma due to the GLC1A gene is often referred to as 1q glaucoma.

The GLC1A gene was identified as encoding a 57 kD protein expressed in the trabecular meshwork (TM) (Stone, et al., "Identification of a Gene That Causes Primary Open Angle Glaucoma," *Science*, 275:668-670 (1997). The expression of the GLC1A gene, and the encoded TM protein, is up-regulated by glucocorticoids (Polansky, et al., "In Vitro Correlates of Glucocorticoid Effects on Intraocular Pressure," *Glaucoma Update IV* (1991); and Polansky, et al., "Cellular Pharmacology and Molecular Biology of the Trabecular Meshwork Inducible Glucocorticoid Response Gene Product,"

*Ophthalmologica*, 211:126-139 (1997). This TM protein is also known as TIGR (trabecular meshwork inducible glucocorticoid response) (Polansky, *Id.*). The glucocorticoid-induction of this TM protein has been suggested to be involved in the generation of glucocorticoid-induced ocular hypertension and glaucoma (Polansky, *Id.*).

5

The GLC1A gene is expressed in other ocular tissues such as the ciliary epithelium (Ortego, et al., "Cloning and Characterization of Subtracted cDNAs from a Human Ciliary Body Library Encoding TIGR, a Protein Involved in Juvenile Open Angle Glaucoma with Homology to Myosin and Olfactomedin," *FEBS Letters*, 413:349-353 (1997) and the retina (Kubota, et al., "A Novel Myosin-like Protein (Myocilin) Expressed in the Connecting Cilium of the Photoreceptor: Molecular Cloning, Tissue Expression, and Chromosomal Mapping," *Genomics*, 41:360-369 (1997). The gene is referred to by several names including GLC1A (Sheffield, *supra*; Sunden, et al., "Fine Mapping of the Autosomal Dominant Juvenile Open Angle Glaucoma (GLC1A) Region and Evaluation of Candidate Genes," *Genome Research*, 6:862-869 (1996); Stone, et al., *supra*, TIGR (Polansky *supra*; Ortego, *supra*, and myocilin (Kubota, *supra*). Mutations GLC1A are not only responsible for juvenile glaucoma, but also a significant subset of adult onset primary open angle glaucoma (Stone, et al., *supra*; Adam, et al., "Recurrent Mutations in a Single Exon Encoding the Evolutionarily Conserved Olfactomedin-Homology Domain of TIGR in Familial Open-Angle Glaucoma," *Human Molecular Genetics*, 6(12):2091-2097 (1997). The 1q glaucoma gene (GLC1A, TIGR) is the subject of Nguyen, et al., U.S. Patent No. 5,606,043, issued February 25, 1997.

10  
15  
20

Several patent applications have disclosed the use of non-steroidal cyclooxygenase inhibitors to treat intraocular pressure (WO 95/17178) through the action of the compounds on trabecular meshwork cells (WO 96/40103 and WO 96/40102). At least some of the beneficial effects of the non-steroidal cyclooxygenase inhibitors are attributed to the inhibition of the expression of myocilin (or TIGR) which is the gene product of GLC1A.

25  
30

It is known that trabecular meshwork cells have glucocorticoid receptors and that glucocorticoid binding with these receptors causes a change in trabecular meshwork cell gene expression. Known manifestations of this change include a reorganization of the cytoskeleton (Wilson, et al., "Dexamethasone Induced Ultrastructural Changes in Cultured Human Trabecular Meshwork Cells, *Cur. Eye Res.*, 12:783-793 (1993), and Clark, et al., "Glucocorticoid-Induced Formation of Cross-Linked Actin Networks in Cultured Human Trabecular Meshwork Cells," *Invest. Ophthalmol. Vis. Sci.*, 35:281-294 (1994)) and increased deposition of the extracellular matrix material in trabecular meshwork cells. As a result, the trabecular meshwork becomes "clogged" and unable to perform one of its most critical functions, that is, serving as a gateway for aqueous humor flow from the anterior chamber of the eye. When the aqueous humor flow out of the eye via the trabecular meshwork is diminished, the intraocular pressure of the eye rises. If this state of elevated intraocular pressure is maintained or frequently occurs, the optic nerve head can be damaged resulting in the loss of visual field. Loss of visual field is the hallmark symptom associated with glaucoma.

In summary, the GLC1A gene product can lead to the development of ocular hypertension and glaucoma in one of two ways: (1) mutations in GLC1A are responsible for most forms of juvenile glaucoma and a subset of adult onset POAG or (2) exposure of some individuals to glucocorticoids leads to increased GLC1A expression in the TM which causes increased aqueous humor outflow resistance and the development of ocular hypertension. The precise mechanism(s) responsible for GLC1A effects on IOP are currently unknown.

### Summary of the Invention

Certain non-steroidal cyclooxygenase inhibitors and their pharmaceutical formulations are useful for treating GLC1A glaucoma. The invention is also directed to methods for controlling GLC1A glaucoma using the non-steroidal cyclooxygenase inhibitors.

### **Brief Description of Drawings**

Figure 1 shows nepafenac concentrations in ocular tissues of rabbits following a single topical dose.

Figure 2 shows the nepafenac concentration calculated from the data in Figure 1.

### **Description of Preferred Embodiments**

Agents which alter the expression of GLC1A in the glaucomatous eye are expected to lower IOP and thereby prevent or inhibit the glaucomatous optic neuropathy which is being driven by elevated IOP. Glucocorticoids upregulate GLC1A expression in the TM of certain individuals. There have been several reports of elevated levels of the natural glucocorticoid cortisol in the aqueous humor and plasma of glaucoma patients (Schwartz, et al., *supra*; Rozsival, et al., *supra*. In addition, certain mutations in GLC1A may alter the expression of GLC1A in the TM tissue of 1q glaucoma patients. Unexpectedly, it has been discovered that certain non-steroidal cyclooxygenase inhibitors inhibit the expression of GLC1A in cultured human TM cells and lower elevated IOP in certain animal models of ocular hypertension. The non-steroidal cyclooxygenase inhibitors act to prevent the expression of GLC1A and the subsequent development of ocular hypertension.


Many non-steroidal cyclooxygenase inhibitors do not readily penetrate the cornea upon topical administration and, therefore, do not reach therapeutic concentrations in the target tissue, the trabecular meshwork.

A series of compounds disclosed in commonly assigned U.S. Patent No. 5,475,034, which showed no significant non-steroidal anti-inflammatory activity *in vitro*, exhibit superior corneal penetration leading to improved ocular bioavailability. The estimated concentration within the anterior chamber following topical ocular



administration of 0.3% nepafenac to rabbits is 24  $\mu$ M (see Figures 1 and 2). This concentration, achieved using a simple formulation without penetration enhancers, is in excess of the parent compounds' COX I and COX II  $IC_{50}$ s. This enhanced bioavailability provides a significant advantage and is unexpected over other non-steroidal anti-inflammatory drugs as well as amide derivatives of non-steroidal anti-inflammatory drugs. The compounds disclosed in the '034 patent, the contents of which are incorporated herein by reference, are ester and amide derivatives of 3-benzoylphenylacetic acid.

The compounds set forth in the '034 patent have the following structure:



(I)

$R = H, C_{1-4}$  (un)branched alkyl,  $CF_3$ ,  $SR^4$

$Y = OR', NR''R'$

$R' = H$  (except when  $Y = OR'$ ),  $C_{1-10}$  (un)branched alkyl, (un)substituted (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below),

$-(CH_2)_nZ(CH_2)_nA$

$n = 2-6$

$n' = 1-6$

$Z = \text{nothing}, O, C=O, OC(=O), C(=O)O, C(=O)NR^3, NR^3C(=O), S(O)_{n^2}, CHOR^3, NR^3$

$n^2 = 0-2$

$R^3 = H, C_{1-6}$  (un)branched alkyl, (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below)

$A = H, OH$ , optionally (un)substituted aryl (substitution as defined by X below),

(un)substituted heterocycle (substitution as defined by X below),  $-(CH_2)_nOR^3$

$R^n = H, OH, OR'$

X and X' independently = H, F, Cl, Br, I, OR', CN, OH,  $S(O)_2R^4$ ,  $CF_3$ ,  $R^4$ ,  $NO_2$

$R^4 = C_{1-6}$  (un)branched alkyl

m = 0-3

m' = 0-5

W = O, H

Preferred compounds for use in the pharmaceutical compositions or method of the present invention are those of Formula I wherein:

$R = H, C_{1-2}$  alkyl

$Y = NR'R''$

$R' = H, C_{1-6}$  (un)branched alkyl,  $-(CH_2)_nZ(CH_2)_m A$

Z = nothing, O,  $CHOR^3$ ,  $NR^3$

$R_3 = H$

A = H, OH, (un)substituted aryl (substitution as defined by X below)

X and X' independently = H, F, Cl, Br, CN,  $CF_3$ , OR',  $SR^4$ ,  $R^4$

$R'' = H$

$R^4 = C_{1-4}$  (un)branched alkyl

m = 0-2

m' = 0-2

W = H

n = 2-4

n' = 0-3

The most preferred compounds for use in the compositions or method of the present invention are 2-Amino-3-(4-fluorobenzoyl)-phenylacetamide; 2-Amino-3-benzoyl-phenylacetamide (nepafenac); and 2-Amino-3-(4-chlorobenzoyl)-phenylacetamide.

For the preferred compound, nepafenac, W=H, R=H, Y=NH<sub>2</sub>, X'=H, X=H, m=3, and m'=5.

The compounds are administered topically to the eye at a concentration of 0.001%-1% (w/v), preferably 0.05-0.5% (w/v) one to three times per day according to the discretion of a skilled clinician.

The following examples are illustrative of formulations which can be used according to the present invention, but are not limiting. "Active Agent" means one or more compounds described by the structure and definition set forth above.

#### Example 1


Active agent	0.01 - 0.5%
Polysorbate 80	0.01%
Benzalkonium Chloride	0.01% + 10% excess
Disodium EDTA	0.1%
Monobasic Sodium Phosphate	0.03%
Dibasic Sodium Phosphate	0.1%
Sodium Chloride	q.s. 290-300 mOsm/Kg
pH adjustment with NaOH and/or HCl	pH 4.2 - 7.4
Water	q.s. 100%

#### Example 2

Active Agent	0.01 - 0.5%
Hydroxypropyl Methylcellulose	0.5%
Polysorbate 80	0.01%
Benzalkonium Chloride	0.01% + 5% excess
Disodium EDTA	0.01%
Dibasic Sodium Phosphate	0.2%
Sodium Chloride	q.s. 290-300 mOsm/Kg
pH adjustment with NaOH and/or HCl	pH 4.2 - 7.4
Water	q.s. 100%

We Claim:

1. A method for treating GLC1A glaucoma which comprises administering a pharmaceutically effective amount of a compound of the structure:



(I)

R = H, C<sub>1-4</sub> (un)branched alkyl, CF<sub>3</sub>, SR<sup>4</sup>

Y = OR', NR''R'

R' = H (except when Y = OR'), C<sub>1-10</sub> (un)branched alkyl, (un)substituted (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below),

—(CH<sub>2</sub>)<sub>n</sub>Z(CH<sub>2</sub>)<sub>n'</sub>A

n = 2-6

n' = 1-6

Z = nothing, O, C=O, OC(=O), C(=O)O, C(=O)NR<sup>3</sup>, NR<sup>3</sup>C(=O), S(O)<sub>n<sup>2</sup></sub>, CHOR<sup>3</sup>, NR<sup>3</sup>

n<sup>2</sup> = 0-2

R<sup>3</sup> = H, C<sub>1-6</sub> (un)branched alkyl, (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below)

A = H, OH, optionally (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below), —(CH<sub>2</sub>)<sub>n</sub>OR<sup>3</sup>

R'' = H, OH, OR'

X and X' independently = H, F, Cl, Br, I, OR', CN, OH, S(O)<sub>n<sup>4</sup></sub>R<sup>4</sup>, CF<sub>3</sub>, R<sup>4</sup>, NO<sub>2</sub>

R<sup>4</sup> = C<sub>1-6</sub> (un)branched alkyl


m = 0-3

m' = 0-5

W = O, H

2. The method of Claim 1 wherein W=H, R=H, Y=NH<sub>2</sub>, X'=H, X=H, m=3, and m'=5.

3. A composition for treating GLCIA glaucoma comprising a pharmaceutically effective amount of a compound of the structure:



(I)

R = H, C<sub>1-4</sub> (un)branched alkyl, CF<sub>3</sub>, SR<sup>4</sup>

Y = OR', NR''R'

R' = H (except when Y = OR'), C<sub>1-10</sub> (un)branched alkyl, (un)substituted (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below),

—(CH<sub>2</sub>)<sub>n</sub>Z(CH<sub>2</sub>)<sub>n</sub>A

n = 2-6

n' = 1-6

Z = nothing, O, C=O, OC(=O), C(=O)O, C(=O)NR<sup>3</sup>, NR<sup>3</sup>C(=O), S(O)<sub>n2</sub>, CHOR<sup>3</sup>, NR<sup>3</sup>

n<sup>2</sup> = 0-2

R<sup>3</sup> = H, C<sub>1-6</sub> (un)branched alkyl, (un)substituted aryl (substitution as defined by X below), (un)substituted heterocycle (substitution as defined by X below)

A = H, OH, optionally (un)substituted aryl (substitution as defined by X below),

(un)substituted heterocycle (substitution as defined by X below), —(CH<sub>2</sub>)<sub>n</sub>OR<sup>3</sup>

R'' = H, OH, OR'

X and X' independently = H, F, Cl, Br, I, OR', CN, OH, S(O)<sub>n2</sub>R<sup>4</sup>, CF<sub>3</sub>, R<sup>4</sup>, NO<sub>2</sub>

R<sup>4</sup> = C<sub>1-6</sub> (un)branched alkyl

m = 0-3

m' = 0-5


W = O, H

4. The composition of Claim 3 wherein W=H, R=H, Y=NH<sub>2</sub>, X'=H, X=H, m=3, and m'=5.

5

FIGURE 1

Concentrations of Unidentified Radioactivity in Ocular Tissues  
Following a Single 0.3% Topical Ocular Dose of  $^{14}\text{C}$ -AL-6515



## INTERNATIONAL SEARCH REPORT

Int. Appl. No.  
PCT/US 98/25744

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/215 A61K31/165 A61K31/19 A61K31/195

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 475 034 A (J. M. YANNI ET AL) 12 December 1995 cited in the application see claims 1-7	3,4
X	GB 2 059 963 A (A.H ROBINS CO INC) 29 April 1981 see claims 1-13 see page 1, line 43 - line 65	3,4
X	EP 0 221 753 A (A. H. ROBINS COMPANY INC.) 13 May 1987 see claims 1-9	3
	-/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "A" document member of the same patent family

Date of the actual completion of the international search

10 March 1999

Date of mailing of the international search report

18/03/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3018

Authorized officer

Siatou, E



# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 98/25744

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 40103 A (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 19 December 1996 cited in the application see claims 1-11, 18-34 see page 9, line 3 - line 21	1-5
A	WO 96 40102 A (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 19 December 1996 cited in the application see page 9, line 11 - page 13, line 5 see claims 1-10, 15-32	1-4
A	RICHARDS J E ET AL: "MAPPING OF A GENE FOR AUTOSOMAL DOMINANT JUVENILE-ONSET OPEN-ANGLE GLAUCOMA TO CHROMOSOME 1Q" AMERICAN JOURNAL OF HUMAN GENETICS, vol. 54, 1 January 1994, pages 62-70, XP002010901 cited in the application	1-4
A	SUNDEN S L F ET AL: "FINE MAPPING OF THE AUTOSOMAL DOMINANT JUVENILE OPEN ANGLE GLAUCOMA (GLC1A) REGION AND EVALUATION OF CANDIDATE GENES" GENOME RESEARCH, vol. 6, no. 9, September 1996, pages 862-869, XP002039329 cited in the application	1-4
A	POLANSKY J R ET AL: "CELLULAR PHARMACOLOGY AND MOLECULAR BIOLOGY OF THE TRABECULAR MESHWORK INDUCIBLE GLUCOCORTICOID RESPONSE GENE PRODUCT" OPHTHALMOLOGICA, vol. 211, no. 3, May 1997, pages 126-139, XP002049456 cited in the application	1-4
A	POLANSKY J R ET AL: "IN VITRO CORRELATES OF GLUCOCORTICOID EFFECTS ON INTRAOCULAR PRESSURE" GLAUCOMA UPDATE, 1 January 1991, pages 20-29, XP000564992 cited in the application	1-4

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/ 25744-

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-2  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 1-2  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/25744

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5475034 A	12-12-1995	AU 689277 B	26-03-1998
		AU 2818495 A	04-01-1996
		CA 2167524 A	14-12-1995
		CN 1129397 A	21-08-1996
		EP 0716600 A	19-06-1996
		JP 8510479 T	05-11-1996
		WO 9533457 A	14-12-1995
GB 2059963 A	29-04-1981	AT 374170 B	26-03-1984
		AT 474580 A	15-08-1983
		AT 379740 B	25-02-1986
		AT 538481 A	15-07-1985
		AU 532359 B	29-09-1983
		AU 6211680 A	02-04-1981
		BE 885393 A	16-01-1981
		BR 8006042 A	07-04-1981
		CA 1128512 A	27-07-1982
		CH 646138 A	15-11-1984
		CS 227012 B	16-04-1984
		DE 3035688 A	16-04-1981
		DK 405780 A,B,	27-03-1981
		EG 15020 A	31-03-1985
		FI 803002 A,B,	27-03-1981
		FR 2465710 A	27-03-1981
		GR 70049 A	26-07-1982
		HK 59383 A	02-12-1983
		IE 50268 B	19-03-1986
		IN 151313 A	26-03-1983
		IN 155995 A	20-04-1985
		IN 156254 A	08-06-1985
		IN 156255 A	08-06-1985
		JP 1041616 B	06-09-1989
		JP 1559426 C	16-05-1990
		JP 56057751 A	20-05-1981
		KE 3307 A	19-08-1983
		LU 82797 A	10-05-1982
		NL 8005346 A	30-03-1981
		PT 71839 B	25-06-1981
		SE 448626 B	09-03-1987
		SE 8006668 A	27-03-1981
		US 4313949 A	02-02-1982
		ZA 8005476 A	25-11-1981
EP 221753 A	13-05-1987	US 4683242 A	28-07-1987
		AT 71358 T	15-01-1992
		AU 596813 B	17-05-1990
		AU 6444786 A	30-04-1987
		DE 3683350 A	20-02-1992
		ES 2039354 T	16-07-1996
		GR 3004278 T	31-03-1993
		IE 59229 B	26-01-1994
		JP 2087427 C	02-09-1996
		JP 7116027 B	13-12-1995
		JP 62126124 A	08-06-1987
WO 9640103 A	19-12-1996	US 5674888 A	07-10-1997
		AU 5754696 A	30-12-1996
		CA 2222930 A	19-12-1996

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Application No

PCT/US 98/25744

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9640103 A		EP 0831802 A	01-04-1998
WO 9640102 A	19-12-1996	US 5599535 A	04-02-1997
		AU 5800896 A	30-12-1996
		CA 2222929 A	19-12-1996
		EP 0831801 A	01-04-1998